In order to understand the role of TIGAR and its potential use as a biomarker in NSCLC, an immunohistochemical analysis of 72 NSCLC patients was conducted, and it showed that both TIGAR and Met expression correlated positively with late stages of lung cancer. This evidence concerns the gene TIGAR and lung cancer.